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Abstract
Purpose We aimed to assess the impact of 18F-fluorodeox-
yglucose (FDG) positron emission tomography (PET) on
the management of patients with suspected large vessel
vasculitis.
Methods An international expert panel determined diagno-
ses and clinical management in patients with suspected
large vessel vasculitis, with and without the results of 18F-
FDG PET, respectively. The accuracy of the clinical
diagnosis and the resulting clinical management with and
without the 18F-FDG PET results were compared using
logistic regression models.
Results The analysis included 30 patients referred to a
tertiary care centre with large vessel vasculitis and 31
controls. 18F-FDG PET had an overall sensitivity of 73.3%
[95% confidence interval (CI) 54.1–87.7%], a specificity of
83.9% (95% CI 66.3–94.5%), a positive predictive value of
81.5% (95% CI 61.9–93.7%) and a negative predictive
value of 76.5% (95% CI 58.8–89.3%). The diagnostic
accuracy of 18F-FDG PET was higher in patients not
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receiving immunosuppressive drugs (93.3 vs 64.5%, p=
0.006). Taken in context with other available diagnostic
modalities, the addition of 18F-FDG PET increased the
clinical diagnostic accuracy from 54.1 to 70.5% (p=0.04).
The addition of 18F-FDG PET increased the number of
indicated biopsies from 22 of 61 patients (36.1%) to 25 of
61 patients (41.0%) and changed the treatment recommen-
dation in 8 of 30 patients (26.7%) not receiving immuno-
suppressive medication and in 7 of 31 patients (22.6%)
receiving immunosuppressive medication.
Conclusion 18F-FDG PET is a sensitive and specific
imaging tool for large vessel vasculitis, especially when
performed in patients not receiving immunosuppressive
drugs. It increases the overall diagnostic accuracy and has
an impact on the clinical management in a significant
proportion of patients.
Keywords Positron emission tomography .
Fluorodeoxyglucose . Giant cell arteritis . Takayasu’s
arteritis . Immunosuppressive drugs
Introduction
The diagnosis of large vessel vasculitis remains a challenge,
especially in patients presenting with nonspecific symptoms
and laboratory tests [1–3]. Standard diagnostic procedures
include biopsy, angiography, ultrasound and magnetic
resonance angiography. These procedures are either invasive,
operator dependent or detect only morphological changes
which mainly occur in later stages of the disease [4–9].
Positron emission tomography (PET) is an operator-
independent, noninvasive metabolic imaging modality
based on the regional distribution of the glucose analogue
18F-fluorodeoxyglucose (FDG). Today, 18F-FDG PET plays
a major role in the management of oncology patients [10].
However, activated inflammatory cells also overexpress
glucose transporters and accumulate increased amounts of
glucose and structurally related substances such as 18F-
FDG [11, 12].
Remarkable images of patients with active vasculitis
have been generated through 18F-FDG PET scans [13–15]
and initial studies indicated that 18F-FDG PET might
become useful for imaging giant cell arteritis [16] and
Takayasu’s arteritis [17]. Large vessel involvement is found
by 18F-FDG PET in about 83% of patients with giant cell
arteritis [18]. Thereby, vascular FDG uptake is found
especially in the subclavian arteries (74%), but also in the
aorta (≥50%) and up to the femoral arteries (37%). The
common 18F-FDG uptake pattern found in giant cell
arteritis is linear and continuous and thoracic vessels are
most frequently affected, followed by the abdominal
vessels [19, 20]. The common 18F-FDG uptake pattern in
early phases of Takayasu’s arteritis is linear and continuous,
while in late phases it becomes rather patchier than
continuous [21]. Recent 18F-FDG PET studies have shown
sensitivities between 56 and 100% for detecting giant cell
arteritis and sensitivities between 83 and 100% for
detecting Takayasu’s arteritis [22–24]. Comparative studies
employing 18F-FDG PET and magnetic resonance imaging
revealed comparable sensitivities of both methods, but 18F-
FDG PET has been shown to identify significantly more
affected vascular regions [19, 25]. Furthermore, 18F-FDG
PET has shown a value for predicting the development of
complications, e.g. thoracic aortic dilatation in patients with
giant cell arteritis [26], and the ability to demonstrate
response after successful initiation of immunosuppressive
treatment [18]. Nevertheless, the diagnostic accuracy that
18F-FDG PET adds to the diagnostic workup as well as its
impact on the clinical management has not been systemat-
ically evaluated yet.
This study therefore aimed to explore the diagnostic
accuracy of 18F-FDG PET on its own and as an add-on test
to the conventional workup as well as its impact on the
clinical management in patients with suspected large vessel
vasculitis.
Materials and methods
A panel of international experts in the field of large vessel
vasculitis determined diagnoses and clinical management in
patients with suspected large vessel vasculitis, with and
without the results of the 18F-FDG PET scan, respectively.
The accuracy of the clinical diagnosis and the resulting
clinical management with and without the 18F-FDG PET
results were compared. The study was approved by the
local Ethics Committee (www.ekbb.ch, reference number
18/10). Because we used archived patient data the study
was deemed exempt from requiring consent.
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Patients
We included patients with (1) suspected large vessel
vasculitis who (2) were referred to our interdisciplinary
tertiary referral centre of the Department of Rheumatology,
University Hospital Basel, Switzerland and who (3) had
received a whole-body PET at the Department of Nuclear
Medicine, University Hospital Basel, (4) in the period
between April 2002 and April 2010. We excluded patients
in case of inconclusive or insufficient follow-up to establish
or rule out large vessel vasculitis.
Reference standard
An expert panel of three experienced board certified
rheumatologists (T.D., U.W. and A.T.) reviewed the
complete patient history with the complete clinical follow-
up including clinical symptoms, laboratory findings, ultra-
sound, computed tomography, magnet resonance imaging,
PET and/or biopsy. Diagnoses were established by consen-
sus and were based on American College of Rheumatology
(ACR) classification criteria from 1990 (n=24) or if not
fulfilled by the combination of clinical symptoms, results of
additional examinations, the exclusion of other diagnoses
and the follow-up after treatment (n=6). Patients were
judged by this panel as disease positive, negative or
intermediate. Patients judged disease negative served as
the control group, and patients judged with intermediate
disease probability were excluded from the study (Fig. 1).
18F-FDG PET imaging
All scans were acquired after a 12-h fast with a dedicated full-
ring PETcamera system. Serum glucose levels were measured
before 18F-FDG application in all patients and were below
180 mg/dl (Glucometer Elite®, Bayer Diagnostics, UK).
Image acquisition was started 45 min after intravenous
injection of 5 MBq/kg body weight of 18F-FDG with the
patient in the supine position. Iterative reconstruction of the
transaxial slices was performed using the ordered subset
expectation maximization (OSEM) algorithm (2 iterations,
8 subsets).
All scans were assessed by a panel of a board certified
nuclear medicine physician, a board certified radiologist and
a physician board certified in nuclear medicine and radiology
(M.A.W., S.B. and H.R.). The panel was blinded to the
patients’ initial clinical, laboratory and imaging results as
well as to the follow-up data. The images were judged as
positive or negative for large vessel vasculitis as previously
described [20]: The severity of large vessel 18F-FDG uptake
was visually graded using a 4-point scale: 0 = no uptake
present, I = low-grade uptake (uptake present but lower
than liver uptake), II = intermediate-grade uptake (similar
to liver uptake) and III = high-grade uptake (uptake higher
than liver uptake). Considering grade II or III uptake in the
thoracic aorta and any visible uptake in other segments as
pathological due to an active arterial inflammation has
previously shown a high sensitivity for large vessel
vasculitis [20].
Clinical scoring
All cases were scored by an international panel of nine board
certified rheumatologists and internists (D.J., I.K., D.B., M.C.
C., P.L., C.S., Z.K., R.W. and R.L.) twice: one time blinded to
the 18F-FDG PET results and one time with the addition of
the 18F-FDG PET results, respectively. All cases were
presented by a computer program, anonymized and in a
random order. The case presentation included all clinical
symptoms, laboratory findings, ultrasound, computed tomog-
raphy and/or magnetic resonance imaging results and the
medication at the time of the 18F-FDG PET scan.
61 Patients with conclusive clinical follow up included
30 Patients included into analyses
67 Patients with conclusive 18FDG PETdata
6 Patients without conclusive clinical follow up excluded
13 Patients without immunosuppressivedrugs
31 Controls included into analyses
17 Controls without immunosuppressive drugs
30 Patients with Large vessel Vasculitis included 31 Controls without Large vessel Vasculitis included
67 Patients scanned for suspected Large Vessel Vasculitis
17 Patients under immunosuppressivedrugs 14 Controls under immunosuppressive drugs
Fig. 1 Patient flow
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Each expert scored (1) the probability of large vessel
vasculitis (in per cent) and based on the average score
patients were judged as disease positive (probability 67–
100%), negative (0–33%) and intermediate (34–66%).
Furthermore, each expert (2) recommended further diag-
nostic workup from a panel of predetermined options
including laboratory, ultrasound, computed tomography,
magnetic resonance imaging and biopsy and (3) scored the
disease extent and activity, each ranging from 1 (minimal)
to 10 (maximal) or “indeterminable” and finally (4) the
recommended drug management, e.g. in untreated patients
to start or not to start glucocorticosteroids and/or other
immunosuppressive drugs and in already treated patients to
escalate or reduce the immunosuppression.
Study endpoints
The predefined study endpoints were (1) the diagnostic
accuracy of 18F-FDG PET for large vessel vasculitis in
patients with and without immunosuppressive drugs, (2) the
accuracy of the clinical diagnosis with and without the
addition of the 18F-FDG PET results, (3) the intention to
biopsy with and without the addition of the 18F-FDG PET
results and (4) the treatment recommendation with and
without the addition of the 18F-FDG PET results.
Statistical analyses
Sensitivity, specificity, positive predictive value, negative
predictive value and diagnostic accuracy of the clinical
scoring with and without 18F-FDG PET results were
calculated using the expert panel assessment as the
reference standard. Differences in proportions were tested
with the χ2 or Fisher’s exact test, as appropriate. Logistic
regression models were used to examine the association of
the pre-PET disease probability with the probability of 18F-
FDG PET ruling out or confirming disease. Logistic
regression was also used to examine the association of
disease probability and the indication of biopsy.
Sensitivity analyses were performed to evaluate the
effects described above in the subgroup of patients with
giant cell arteritis.
All discrete variables are described by counts (percent-
age) and continuous variables by their median (range),
unless stated otherwise. Two-sided p values of <0.05 were
considered to indicate statistical significance.
Results
Overall, 67 patients were considered for inclusion. Of
these, large vessel vasculitis was confirmed in 30 (44.8%;
24 giant cell arteritis, 6 Takayasu’s arteritis) and ruled out
in 31 (46.3%). Six patients (8.9%) with inconclusive
follow-up data were excluded from the study (Fig. 1). Of
61 patients included in this study, 28 (45.9%) received
corticosteroids and 12 (19.7%) received other immunosup-
pressive drugs (azathioprine, cyclophosphamide, cyclospor-
ine or methotrexate). A total of 30 patients (49.2%) were
PET scanned before and 31 patients (50.8%) were scanned
after the start of steroid and/or other immunosuppressive
drugs. The patients’ baseline characteristics are shown in
Table 1.
The diagnostic value of 18F-FDG PET alone
Overall, 27 18F-FDG PET scans were positive for large
vessel vasculitis (44.3%; 22 true-positives, 5 false-positives)
and 34 were considered negative (55.7%; 26 true-negatives,
8 false-negatives). None of the scans were assessed as
inconclusive. The resulting sensitivity was 73.3% [95%
confidence interval (CI) 54.1–87.7%], the specificity was
83.9% (95% CI 66.3–94.5%), the positive predictive value
was 81.5% (95% CI 61.9–93.7%) and the negative predictive
value was 76.5% (95% CI 58.8–89.3%). The overall
diagnostic accuracy of 18F-FDG PET was 78.7%, i.e. 48 of
61 patients were labelled correctly (Table 2). In the
subgroup of patients with giant cell arteritis the diagnostic
accuracy was 81.8%. All eight false-negative 18F-FDG
PET scans were performed under immunosuppressive drugs
(Fig. 2).
The diagnostic value of 18F-FDG PET
with and without immunosuppressive drugs
In 30 patients without immunosuppressive drugs, 13 scans
were truly positive, 2 were falsely positive, 15 were truly
negative and none were falsely negative. The resulting
sensitivity was 99.6% (95% CI 69.8–100%), the specificity
was 86.1% (95% CI 58.6–96.4%), the positive predictive
value was 84.4% (95% CI 54.4–96.0%) and the negative
predictive value was 99.6% (95% CI 73.2–100%). The
diagnostic accuracy of 18F-FDG PET in patients without
immunosuppressive drugs was 93.3% (28 of 30 patients
were labelled correctly, Table 2).
In the 31 patients on immunosuppressive drugs on the
other hand, 9 scans were truly positive, 3 were falsely positive,
11 were truly negative and 8 were falsely negative. The
resulting sensitivity was 52.9% (95% CI 27.8–77.0%), the
specificity was 78.6% (95% CI 49.2–95.3%), the positive
predictive value was 75.0% (95% CI 42.8–94.5%) and the
negative predictive value was 57.9% (95% CI 33.5–79.7%).
The diagnostic accuracy of 18F-FDG PET in patients on
immunosuppressive drugs was 64.5% (20 of 31 patients
were labelled correctly), significantly lower than in patients
without immunosuppressive drugs (p=0.006).
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The diagnostic value of 18F-FDG PET in the clinical
context
With all diagnostic workup data available except the 18F-
FDG PET results, of 30 disease-positive patients 14
(46.7%) were identified correctly by the scoring board, 5
(16.7%) were falsely scored disease negative, while 11
(36.6%) were scored as intermediate probability. Of 31
disease-negative controls, 18 were correctly identified as
disease negative (58.1%), 4 were falsely scored as disease
positive (12.9%), while 9 patients (29.0%) were scored as
intermediate probability. Without the 18F-FDG PET results,
32 of 61 patients were diagnosed correctly (diagnostic
accuracy 54.1%, Table 2).
The detailed expert scoring results are presented in Fig. 6
of the Appendix.
The addition of the 18F-FDG PET results changed the
diagnosis in 18 patients (27.9%): 14 times from an
intermediate probability or incorrect diagnosis to the correct
diagnosis, 2 times from the correct diagnosis to an
intermediate probability and 2 times from the correct
diagnosis to a wrong diagnosis. Overall, the addition of
the 18F-FDG PET result reduced the number of patients
scored undetermined from 20 to 10.
Of 30 disease-positive patients 25 (83.3%) were identi-
fied correctly, 3 (10.0%) were falsely scored disease
negative, while 2 (6.7%) were scored as intermediate
probability. Of the 31 disease-negative controls 18
(58.1%) were correctly identified as disease negative, 5
(16.1%) were falsely scored as disease positive, while
8 (25.8%) were scored as undetermined. With the 18F-FDG
PET results, 43 of 61 patients were diagnosed correctly
(diagnostic accuracy 70.5%), significantly more than
without the 18F-FDG PET data (p=0.04). In the subgroup
of patients with giant cell arteritis the addition of the 18F-
FDG PET results increased the diagnostic accuracy from
50.9 to 69.1% (p=0.05).
18F-FDG PET had a higher additional diagnostic
value in confirming than in ruling out large vessel
vasculitis. In disease-positive patients, the addition of
18F-FDG PET significantly changed the scored probability
of disease from a median of 62.2% (range 20.6–97.4%) to
Table 1 Baseline characteristics
aThe results were derived from
27 temporal artery biopsies and
2 aortic biopsies; biopsy-
positive is defined as mononu-
clear cell infiltration of the
temporal artery with or without
giant cells
Characteristic Finding Large vessel vasculitis
(n=30)
Controls
(n=31)
Gender Female 22 18
Male 8 13
Age (years) Median 70.6 65.1
Range 17.6–81.4 24.3–86.9
Clinical findings Age at onset of symptoms ≥50 years 22 28
New headache 14 12
Temporal artery abnormality 9 1
Elevated erythrocyte
sedimentation rate
29 23
Age at onset of disease ≤40 years 4 3
Claudication of an extremity 5 2
Decreased brachial artery pulse 3 0
Different systolic blood pressure in
both arms
7 1
Bruit over the subclavian arteries or
the aorta
6 2
Narrowing/occlusion of entire aorta 5 5
Biopsya Positive 12 0
Negative 9 8
Diagnosis Giant cell arteritis 24 0
Takayasu’s arteritis 6 0
Immunosuppressive
treatment
Total 23 19
Glucocorticosteroids 16 12
Methotrexate 7 3
Azathioprine 0 2
Cyclophosphamide 0 1
Cyclosporine 0 1
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89.9% (5.3–98.1%, p=0.001, Fig. 3). On the contrary, in
the disease-negative controls the addition of the 18F-FDG
PET results did not significantly change the scored
probability [25.6% (0.8–88.3%) to 16.7% (1.8–93%), p=
0.65, Fig. 3].
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Fig. 2 18F-FDG PET scans of two patients with giant cell arteritis. The
scan in a 68-year-old womanwithout immunosuppressive drugs (a) shows
pathologically elevated 18F-FDG uptake in the aorta and its major
branches. These findings changed the treatment recommendation from
‘no immunosuppressive drugs’ to ‘start immunosuppressive drugs’. On
the contrary, the scan in a 52-year-old woman under 40 mg per day
prednisone (b) shows no elevated 18F-FDG uptake in the large vessels,
with, however, no change in the recommended clinical management
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Fig. 3 Diagnostic value of 18F-FDG PET in the clinical context. In
disease-positive patients (p=0.001), but not in the controls (p=0.65)
the addition of 18F-FDG PET significantly changed the scored
probability of disease
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The impact of 18F-FDG PET on the biopsy
recommendation
With all the diagnostic workup data available except the
18F-FDG PET results, biopsy was scored to be indicated in
22 patients (36.1%). The addition of the 18F-FDG PET
results changed the biopsy indication from ‘yes’ to ‘no’ in
four patients and from ‘no’ to ‘yes’ in seven patients. As a
result, the addition of the 18F-FDG PET results did not
significantly change the number of patients with indicated
biopsy to 25 (41.0%, Fig. 4a). Logistic regression revealed
a positive correlation of higher biopsy rates when higher
probabilities of large vessel vasculitis were scored (Fig. 4b).
The impact of 18F-FDG PET on treatment recommendation
The impact of 18F-FDG PET on the medical management
was assessed in patients receiving and not receiving
immunosuppressive medication.
Of all 61 patients, 30 (49.2%) had not received any
immunosuppressive medication. With all diagnostic workup
data available except the 18F-FDG PET results, glucocorti-
costeroids were considered to be indicated in 11 of the 30
patients, while no change in management was recommended
in 19 patients. The addition of the 18F-FDG PET result
changed the indicated management in eight patients (26.7%,
Fig. 5a). Four patients were changed from no drugs to
corticosteroids, one patient was changed from no drugs to
corticosteroids with additional immunosuppressives, while
three patients were changed from corticosteroids to cortico-
steroids with additional immunosuppressives.
Thirty-one patients (50.8%) were receiving immuno-
suppressive medication. Without the 18F-FDG PET
results, a dose increase was scored to be indicated in 3, a
decrease to be indicated in 7, while no change in
management was indicated in 21 patients. The addition
of the 18F-FDG PET results changed the management in
seven patients (22.6%, Fig. 5b). Two patients were shifted
from ‘no change’ to ‘dose increase’ and five patients were
shifted from ‘no change’ to ‘dose decrease’. In total, 18F-
FDG PET changed the treatment recommendation in 15
patients. In 8 of these 15 patients (53.3%) the 18F-FDG
PET had also changed the overall diagnosis.
Discussion
The present results indicate that 18F-FDG PET is a sensitive
and specific imaging tool that increases the overall
diagnostic accuracy for large vessel vasculitis in the context
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Fig. 4 18F-FDG PET and
biopsy frequency. The addition
of the 18F-FDG PET results did
not significantly change biopsy
rates (a). Logistic regression
revealed a positive correlation of
higher biopsy rates with higher
probabilities of large vessel
vasculitis (b)
Start Corticosteroids
& Immunosuppressives
n=0
Increase Dose
n=3
Decrease Dose
n=7+3 after PET No changes
a Patients not on Immunosuppressive Drugs (n=30) b Patients on Immunosuppressive Drugs (n=31)
No Change
in Medication
n=19
No Change
in Medication
n=21
Start 
Corticosteroids
n=11
After PET
Before PET
Fig. 5 18F-FDG PET and clini-
cal management. The addition
of the 18F-FDG PET result
changed the indicated manage-
ment in 26.7% of patients naïve
to immunosuppressive drugs (a)
and in 22.6% of patients under
immunosuppressive drugs (b)
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of the available diagnostic results. Thereby, 18F-FDG PET
has an impact on the medical management in a significant
proportion of patients.
The sensitivities and specificities found are compara-
ble to previously published results [22]. The underlying
principle of PET imaging in inflammatory processes is the
increased accumulation of glucose and structurally related
substances such as 18F-FDG into inflammatory cells [11,
12]. Alternatively, magnet resonance imaging, which is
also used for imaging large vessel vasculitis, mainly
analyses the thickness of the vascular wall [27]. We have
previously shown that the accuracy of 18F-FDG PET
increases in the state of active inflammation [20]. In line
with these results, previous studies have indicated a lower
diagnostic value of 18F-FDG PET in patients with
suspected large vessel vasculitis under immunosuppres-
sive drugs [28, 29]. The present study systematically
evaluated the diagnostic accuracy of 18F-FDG PET with
and without immunosuppressive medication and found a
significantly reduced diagnostic value in patients on
immunosuppressive drugs. Consequently, 18F-FDG PET
should, whenever feasible, be performed in an interval
without immunosuppressive drugs.
Until now it has remained elusive whether adding
18F-FDG PET results to the usual diagnostic workup for
large vessel vasculitis would increase diagnostic accuracy.
Here, the present study showed that 18F-FDG PET allows
the overall accuracy of the diagnostic workup to be
significantly increased. Furthermore, the present results
showed that 18F-FDG PET principally had a higher value
in confirming than ruling out disease. The increase of
diagnostic accuracy by 18F-FDG PET is relevant to the
diagnostic workup of each individual patient as well as to
the current efforts to establish diagnostic and classification
criteria for systematic vasculitis [2]. 18F-FDG PET
changed the indicated medical management in both
groups, patients with and without immunosuppressive
drugs, respectively. Thereby, with changes in management
in about one of four patients, the extent of the influence of
18F-FDG PET was similar in both groups. These results
demonstrate that 18F-FDG PET increases diagnostic
accuracy and changes medical management in a signifi-
cant proportion of patients.
One of the aims of noninvasive PET imaging is to
provide a whole-body status and to replace local
invasive procedures such as biopsies. In this study, the
addition of 18F-FDG PET did not decrease the frequency
of recommended biopsies despite the increased diagnostic
value. We found a positive correlation between the
probability of larger vessel vasculitis and the probability
of recommendation for biopsy. Higher pre-test probabili-
ties increased the rate of recommended biopsies. These
results indicate that, given the current state of evidence,
18F-FDG PET is unlikely to replace biopsy procedures in
the near future.
This study has strengths and limitations. First, large
vessel vasculitis is a rare condition and accordingly the
present cohort is relatively small. Nevertheless, the study
was sufficiently powered to obtain significant results.
Secondly, the present study shows that 18F-FDG PET
increases the diagnostic accuracy of experts in the field of
large vessel vasculitis that scored the disease probability
on a scale from 0 to 100%, analogous to the visual
analogue scale [30]. The effect on the diagnostic accuracy
in less experienced physicians remains elusive. Third, the
reference standard may be influenced by results of 18F-
FDG PET potentially leading to incorporation bias since
the reference panel based its decisions on the complete
clinical follow-up of patients including all diagnostic test
results. Fourth, the study cohort comprises patients with
giant cell arteritis and Takayasu’s arteritis. Accordingly,
sensitivity analyses were performed that showed similar
results in the cohort of giant cell arteritis patients. In
accordance with previous studies [31], we were not able to
detect enhanced uptake in temporal vessels. This limita-
tion is mainly due to the high FDG uptake in the brain and
the small diameter of the temporal arteries. Next genera-
tion PET scanners, however, might be able to reliably
measure FDG uptake in temporal vessels. Finally, the
study showed that 18F-FDG PET has an impact on the
medical management in a significant proportion of
patients. In a next step further studies are warranted to
evaluate the potential improvement in the clinical outcome
by the additional use of 18F-FDG PET.
Previous studies had already assessed the diagnostic
performance of 18F-FDG PET in patients with and
without immunosuppressive medication. The present
study is the first to systematically analyse the impact of
18F-FDG PET on biopsy and treatment recommendations.
The results demonstrate the additional diagnostic value of
18F-FDG PET in patients with suspected large vessel
vasculitis and they define the conditions under which 18F-
FDG PET is anticipated to be most helpful. Whenever
feasible, 18F-FDG PET should be performed when the
patient is not receiving immunosuppressive drugs. 18F-
FDG PET increases the overall diagnostic accuracy and
has an impact on the medical management in a significant
proportion of patients.
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